純利益率
2012年以降
計算
AbbVie Inc.、純利益率、長期トレンド計算
| 純利益率 | = | 100 | × | アッヴィに帰属する当期純利益1 | ÷ | 純売上高1 | |
|---|---|---|---|---|---|---|---|
| 2024/12/31 | 7.59% | = | 100 | × | 4,278) | ÷ | 56,334) |
| 2023/12/31 | 8.95% | = | 100 | × | 4,863) | ÷ | 54,318) |
| 2022/12/31 | 20.39% | = | 100 | × | 11,836) | ÷ | 58,054) |
| 2021/12/31 | 20.54% | = | 100 | × | 11,542) | ÷ | 56,197) |
| 2020/12/31 | 10.08% | = | 100 | × | 4,616) | ÷ | 45,804) |
| 2019/12/31 | 23.69% | = | 100 | × | 7,882) | ÷ | 33,266) |
| 2018/12/31 | 17.36% | = | 100 | × | 5,687) | ÷ | 32,753) |
| 2017/12/31 | 18.82% | = | 100 | × | 5,309) | ÷ | 28,216) |
| 2016/12/31 | 23.22% | = | 100 | × | 5,953) | ÷ | 25,638) |
| 2015/12/31 | 22.50% | = | 100 | × | 5,144) | ÷ | 22,859) |
| 2014/12/31 | 8.89% | = | 100 | × | 1,774) | ÷ | 19,960) |
| 2013/12/31 | 21.97% | = | 100 | × | 4,128) | ÷ | 18,790) |
| 2012/12/31 | 28.70% | = | 100 | × | 5,275) | ÷ | 18,380) |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31).
1 百万米ドル
競合他社との比較
AbbVie Inc.、純利益率、長期トレンド、競合他社との比較
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024/12/31 | 7.59% | 12.77% | -18.53% | 16.33% | 23.51% | 1.68% | 15.84% | 26.68% | 12.62% | 31.07% | 14.77% | -4.86% |
| 2023/12/31 | 8.95% | 24.96% | 17.83% | 19.94% | 15.36% | 21.03% | 41.28% | 0.61% | 3.56% | 30.14% | 13.99% | 36.68% |
| 2022/12/31 | 20.39% | 26.42% | 13.71% | 22.91% | 21.88% | 17.02% | 18.90% | 24.49% | 31.01% | 35.64% | 15.47% | 37.20% |
| 2021/12/31 | 20.54% | 24.25% | 15.08% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 26.76% | 50.25% | 19.70% | 30.92% |
| 2020/12/31 | 10.08% | 29.97% | -21.20% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | 22.53% | 41.35% | 19.79% | 43.70% |
| 2019/12/31 | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 28.27% |
| 2018/12/31 | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| 2017/12/31 | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| 2016/12/31 | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| 2015/12/31 | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| 2014/12/31 | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| 2013/12/31 | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| 2012/12/31 | 28.70% | 26.11% | 11.12% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31).
産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
AbbVie Inc.、純利益率、長期トレンド、産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
| AbbVie Inc. | 製薬、バイオテクノロジー、ライフサイエンス | |
|---|---|---|
| 2024/12/31 | 7.59% | 12.30% |
| 2023/12/31 | 8.95% | 17.95% |
| 2022/12/31 | 20.39% | 22.55% |
| 2021/12/31 | 20.54% | 23.38% |
| 2020/12/31 | 10.08% | 14.07% |
| 2019/12/31 | 23.69% | 23.22% |
| 2018/12/31 | 17.36% | 19.82% |
| 2017/12/31 | 18.82% | 13.06% |
| 2016/12/31 | 23.22% | 20.78% |
| 2015/12/31 | 22.50% | 21.17% |
| 2014/12/31 | 8.89% | 21.24% |
| 2013/12/31 | 21.97% | 21.99% |
| 2012/12/31 | 28.70% | 18.53% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31).
業界との比較: 医療
AbbVie Inc.、純利益率、長期トレンド、業界との比較: 医療
| AbbVie Inc. | 医療 | |
|---|---|---|
| 2024/12/31 | 7.59% | 7.02% |
| 2023/12/31 | 8.95% | 9.24% |
| 2022/12/31 | 20.39% | 11.62% |
| 2021/12/31 | 20.54% | 12.42% |
| 2020/12/31 | 10.08% | 8.45% |
| 2019/12/31 | 23.69% | 11.58% |
| 2018/12/31 | 17.36% | 9.92% |
| 2017/12/31 | 18.82% | 8.05% |
| 2016/12/31 | 23.22% | 10.68% |
| 2015/12/31 | 22.50% | 11.77% |
| 2014/12/31 | 8.89% | 12.15% |
| 2013/12/31 | 21.97% | 12.81% |
| 2012/12/31 | 28.70% | 11.86% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31).